Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc. > Dr. Black article on Phase 2 Trial of Atezolizumab
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(12061)
•••
Comment by ScienceFirston Aug 23, 2023 4:58pm
176 Views
Post# 35602683

RE:RE:RE:Dr. Black article on Phase 2 Trial of Atezolizumab

RE:RE:RE:Dr. Black article on Phase 2 Trial of Atezolizumab

Thadeush ... You are correct.  Good observation.  

Even NHL's Blackwacks star Jonatan Toews got the COVID-19 long and missed one complete season and decided to take another one off struggling with immune system issues

https://www.sportsnet.ca/nhl/blackhawks-jonathan-toews-reveals-battle-chronic-immune-response-syndrome/sn-amp/

https://abc7chicago.com/amp/jonathan-toews-long-covid-illness-chronic-immune-response-syndrome/12849787/



So, contrary to FERRING's gene therapy, our treatment can be given to immunosupressed and immuno-compromised.


___________

 

thadeush - (8/23/2023 4:29:52 PM)
RE:RE:Dr. Black article on Phase 2 Trial of Atezolizumab
And it's worth noting that as COVID, which attacks T-cells and is more and more being compared to HIV, runs in checked through the population there will be a LOT of people who are immunosupressed and immuno-compromised.

https://time.com/6265510/covid-19-weaken-immune-system/

German Health Minister: "Anyone who gets infected with corona more often runs the risk of developing an incurable immune deficiency." 
 
Roughly 50 scientific papers showing this now.
 
https://www.archyde.com/studies-give-cause-for-concern-lauterbach-warns-of-incurable-immune-deficiency-caused-by-corona/

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities